DFX Intelligence

Data Factory

Avalo

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:b202aa68-aeb5-48b8-b485-79660575cd76

Data as of Sep 18, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 19, 2026, 3:31 AM UTC and rebuilt at most every 15 minutes.

Relationships: 6
Dated events: 2
On other graphs: 1
Observed: Sep 15, 2026 to Sep 18, 2026
4 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

Avalo

Venture-backed company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Owners: Greycroft LP, Petrichor Healthcare Capital Management LP
Owned since: Jan 1, 2025
Add-ons on file: 2add-on transactions linked to this company on the graph
Add-ons evidenced: 1derived0 in 24 months, from sponsor and platform websites and press; record tier discovery, not independently verified
Latest add-on: Mar 27, 2024
Transactions: 2
Investors: 2

Transactions

Announced	Type	Headline	EV	Basis
Mar 27, 2024	Add on acquisition	Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	n/a	n/a
Mar 27, 2024	Add on acquisition	Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	n/a	n/a

Investors

Investor	Class	Role	Control	Invested	Status
Greycroft LP	Venture with PE activity	unknown	unknown	Jan 1, 2025	active
Petrichor Healthcare Capital Management LP	Buyout	platform	unknown	n/a	active

Relationships

Invested in (2)

← Petrichor Healthcare Capital Management LPFirmplatform
factNews and newswire, DFX's own graph, The subject's own site
← Greycroft LPFirmunknown
Jan 1, 2025 to presentfactThe subject's own site

Add on of (1)

← Phase 2-readyCompany
Mar 27, 2024 to presentfactNews and newswire

Dated events

Occurred
Mar 27, 2024
Add-on acquired
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Phase 2-ready News and newswireobserved 2 days ago
Occurred
Mar 27, 2024
Add-on acquired
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Phase 2-ready News and newswireobserved 2 days ago

Provenance

Graph: Private Equity
Canonical id: dfx:pe:b202aa68-aeb5-48b8-b485-79660575cd76
First observed: Sep 15, 2026
Last observed: Sep 18, 2026 8 h ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Avalo

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:b202aa68-aeb5-48b8-b485-79660575cd76

Data as of Sep 18, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 19, 2026, 3:31 AM UTC and rebuilt at most every 15 minutes.

Announced

Type

Headline

Basis

Mar 27, 2024

Add on acquisition

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

n/a

Mar 27, 2024

Add on acquisition

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

n/a

Investor

Class

Role

Control

Invested

Status

Greycroft LP

Venture with PE activity

unknown

Jan 1, 2025

active

Petrichor Healthcare Capital Management LP

Buyout

platform

unknown

n/a

active